Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease
- PMID: 29682983
- DOI: 10.1177/1945892418770260
Long-term Clinical Outcomes of Aspirin Desensitization With Continuous Daily Aspirin Therapy in Aspirin-exacerbated Respiratory Disease
Abstract
Background Aspirin-exacerbated respiratory disease (AERD), also known as Samter's triad or aspirin (ASA)-intolerant asthma, affects 7% of asthmatics and has a higher prevalence in those with chronic rhinosinusitis and concomitant nasal polyposis. ASA desensitization with daily ASA therapy is a uniquely beneficial treatment for this disease entity and has been shown to have a significant impact on symptom scores, polyp disease, and need for systemic corticosteroids. However, no long-term studies have demonstrated whether or not ASA therapy remains safe and beneficial for these patients beyond 5-10 years. Objective This study was designed to determine the clinical course of AERD patients desensitized between 1995 and 2010. Methods A 20-question survey was distributed to patients who successfully completed ASA desensitization between January 1995 and April 2010. The questions were designed to assess ASA safety and longitudinal effects of ASA therapy in AERD. Results Of the 285 patients contacted, 92 (32%) completed the questionnaire. Average length of follow-up was 15 years. Of survey responders, 35 patients had discontinued ASA therapy. Although adverse reactions occurred, many also discontinued due to lack of efficacy or need for surgery. For those remaining on ASA (62%), significant improvement in sense of smell, asthma, sinus, and allergic rhinitis scores were noted ( P ≤ .001). The majority of ASA patients (68%) had a positive response to treatment and did not require further sinus surgery. However, ASA therapy did not delay the time to next sinus/polyp surgery ( P = .27) or reduce total number of sinus surgeries ( P = .56) compared to those who stopped treatment. Nearly 85% of AERD patients on ASA therapy found it to be helpful in improving airway disease and quality of life. Conclusion Aspirin desensitization followed by daily maintenance ASA therapy appears to be safe and effective even after 10+ years of continuous use.
Keywords: NSAID intolerance; Samter’s triad; aspirin desensitization; aspirin side effects; aspirin-exacerbated respiratory disease; aspirin-intolerant asthma; chronic rhinosinusitis; nasal polyps; questionnaire; safety; survey.
Similar articles
-
Objective and subjective sinonasal and pulmonary outcomes in aspirin desensitization therapy: A prospective cohort study.Auris Nasus Larynx. 2019 Aug;46(4):526-532. doi: 10.1016/j.anl.2018.12.002. Epub 2018 Dec 19. Auris Nasus Larynx. 2019. PMID: 30577986
-
Symptom Control of Patients With Chronic Rhinosinusitis With Nasal Polyps Under Maintenance Therapy With Daily Acetylsalicylic Acid.Am J Rhinol Allergy. 2020 Jul;34(4):554-563. doi: 10.1177/1945892420912362. Epub 2020 Mar 24. Am J Rhinol Allergy. 2020. PMID: 32208749
-
Long-term sinonasal outcomes of aspirin desensitization in aspirin exacerbated respiratory disease.Otolaryngol Head Neck Surg. 2014 Oct;151(4):575-81. doi: 10.1177/0194599814545750. Epub 2014 Aug 12. Otolaryngol Head Neck Surg. 2014. PMID: 25118195
-
Current complications and treatment of aspirin-exacerbated respiratory disease.Expert Rev Respir Med. 2016 Dec;10(12):1305-1316. doi: 10.1080/17476348.2016.1258306. Epub 2016 Nov 17. Expert Rev Respir Med. 2016. PMID: 27817219 Review.
-
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.J Allergy Clin Immunol. 2021 Mar;147(3):827-844. doi: 10.1016/j.jaci.2020.10.043. Epub 2020 Dec 9. J Allergy Clin Immunol. 2021. PMID: 33307116 Free PMC article. Review.
Cited by
-
Mast Cells in Aspirin-Exacerbated Respiratory Disease.Curr Allergy Asthma Rep. 2024 Feb;24(2):73-80. doi: 10.1007/s11882-024-01125-1. Epub 2024 Jan 13. Curr Allergy Asthma Rep. 2024. PMID: 38217825 Review.
-
GEMA 5.3. Spanish Guideline on the Management of Asthma.Open Respir Arch. 2023 Sep 19;5(4):100277. doi: 10.1016/j.opresp.2023.100277. eCollection 2023 Oct-Dec. Open Respir Arch. 2023. PMID: 37886027 Free PMC article.
-
Aspirin-exacerbated respiratory disease: Updates in the era of biologics.Ann Allergy Asthma Immunol. 2023 Sep;131(3):317-324. doi: 10.1016/j.anai.2023.05.016. Epub 2023 May 22. Ann Allergy Asthma Immunol. 2023. PMID: 37225000 Review.
-
Pathomechanisms of AERD-Recent Advances.Front Allergy. 2021 Sep 10;2:734733. doi: 10.3389/falgy.2021.734733. eCollection 2021. Front Allergy. 2021. PMID: 35387030 Free PMC article. Review.
-
Patient-Reported Control of Asthma, Nasal Polyposis, and Middle-Ear Symptoms in NSAID-Exacerbated Respiratory Disease.Front Allergy. 2021 Jul 15;2:716169. doi: 10.3389/falgy.2021.716169. eCollection 2021. Front Allergy. 2021. PMID: 35386973 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
